Brief: Maxcyte Says FY Rev Expected To Increase About 19 Pct
Jan 15 (Reuters) - MaxCyte Inc MXCT.L :
* MAXCYTE INC - 2018 FY REVENUES EXPECTED TO INCREASE ABOUT
19%
YOY TO ABOUT $16.7M
* MAXCYTE INC - REVENUE ACCELERATED IN SECOND HALF OF 2018
INCREASING APPROXIMATELY 25% OVER SECOND HALF OF 2017
* MAXCYTE INC - EBITDA FOR FY EXPECTED TO BE AN IMPROVEMENT
ON
MARKET EXPECTATIONS
* MAXCYTE INC - ANTICIPATES CONTINUED STRONG GROWTH FOR
CURRENT
2019 FINANCIAL YEAR
Source text for Eikon: ID:nRSO0746Na
Further company coverage: MXCT.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on MaxCyte
See all newsMaxCyte, Inc. MaxCyte, Inc. - MXCR - Second Price Monitoring Extn
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Price Monitoring Extension
Brief: Maxcyte And Allogene Therapeutics Sign Clinical And Commercial License Agreement To Enable The Advancement Of Allogeneic Car T (Allocar T™) Therapies
Brief: Maxcyte Signs Agreement With KSQ Therapeutics
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Agreement with KSQ Therapeutics